Tapinarof for psoriasis and atopic dermatitis: 15 years of clinical research.
Journal
Journal of the European Academy of Dermatology and Venereology : JEADV
ISSN: 1468-3083
Titre abrégé: J Eur Acad Dermatol Venereol
Pays: England
ID NLM: 9216037
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
23
09
2022
accepted:
13
01
2023
medline:
15
5
2023
pubmed:
29
1
2023
entrez:
28
1
2023
Statut:
ppublish
Résumé
Tapinarof is a topical, aryl-hydrocarbon receptor agonist that has recently received FDA-approval for the treatment of psoriasis. This novel therapeutic has also been shown to be effective for atopic dermatitis and is currently in phase 3 for this indication. Beyond good efficacy and fast onset of action in patients with psoriasis, the clinical response to tapinarof is notable for durable remission or near remission, maintained for an average of 130 days beyond treatment discontinuation in patients with psoriasis in phase 3 studies. Tapinarof is usually well tolerated but can induce a follicular inflammatory reaction and dermatitis in some patients. This narrative review covers the historical development of this molecule, safety and efficacy data from clinical trials conducted with various topical formulations, and practical considerations derived from our 15 years of clinical trial experience with the drug.
Substances chimiques
tapinarof
84HW7D0V04
Resorcinols
0
Stilbenes
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1168-1174Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2023 European Academy of Dermatology and Venereology.
Références
Li J, Chen G, Wu H, Webster JM. Identification of two pigments and a hydroxystilbene antibiotic from Photorhabdus luminescens. Appl Environ Microbiol. 1995;61(12):4329-33.
Hu K, Webster JM. Antibiotic production in relation to bacterial growth and nematode development in Photorhabdus-Heterorhabditis infected Galleria mellonella larvae. FEMS Microbiol Lett. 2000;189(2):219-23.
Welichem Biotech Inc., Inventor. Polyhydroxystilbenes and stilbene oxides as antisoriatic agents and protein kinase inhibitors. [cited 2001 Jun 14]. US patent WO2001042231.
Bissonnette R, Bolduc C, Maari C, Nigen S, Webster JM, Tang L, et al. Efficacy and safety of topical WBI-1001 in patients with mild to moderate psoriasis: results from a randomized double-blind placebo-controlled, phase II trial. J Eur Acad Dermatol Venereol. 2012;26(12):1516-21.
Bissonnette R, Chen G, Bolduc C, Maari C, Lyle M, Tang L, et al. Efficacy and safety of topical WBI-1001 in the treatment of atopic dermatitis: results from a phase 2A, randomized, placebo-controlled clinical trial. Arch Dermatol. 2010;146(4):446-9.
Zhang J, Cai L, Zheng M. A novel topical treatment for plaque psoriasis: benvitimod/tapinarof. J Am Acad Dermatol. 2022;86(3):e137-8.
Peppers J, Paller AS, Maeda-Chubachi T, Wu S, Robbins K, Gallagher K, et al. A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis. J Am Acad Dermatol. 2019;80(1):89-98.e3.
Robbins K, Bissonnette R, Maeda-Chubachi T, Ye L, Peppers J, Gallagher K, et al. Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasis. J Am Acad Dermatol. 2019;80(3):714-21.
Tapinarof cream (Vtama) for psoriasis. Med Lett Drugs Ther. 2022;64(1656):e128-9.
Smith SH, Jayawickreme C, Rickard DJ, Nicodeme E, Bui T, Simmons C, et al. Tapinarof is a natural AhR agonist that resolves skin inflammation in mice and humans. J Invest Dermatol. 2017;137(10):2110-9.
Fernández-Gallego N, Sánchez-Madrid F, Cibrian D. Role of AHR ligands in skin homeostasis and cutaneous inflammation. Cell. 2021;10(11):3176.
van den Bogaard EH, Perdew GH. The enigma of AHR activation in the skin: interplay among ligands, metabolism, and bioavailability. J Invest Dermatol. 2021;141(6):1385-8.
van den Bogaard EH, Esser C, Perdew GH. The aryl hydrocarbon receptor at the forefront of host-microbe interactions in the skin: a perspective on current knowledge gaps and directions for future research and therapeutic applications. Exp Dermatol. 2021;30(10):1477-83.
Qiao P, Zhang C, Yu J, Shao S, Zhang J, Fang H, et al. Quinolinic acid, a tryptophan metabolite of the skin microbiota, negatively regulates NLRP3 inflammasome through AhR in psoriasis. J Invest Dermatol. 2022;142(8):2184-93.e6.
Bissonnette R, Stein Gold L, Rubenstein DS, Tallman AM, Armstrong A. Tapinarof in the treatment of psoriasis: a review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent. J Am Acad Dermatol. 2021;84(4):1059-67.
Furue M. Regulation of filaggrin, loricrin, and involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: pathogenic implications in atopic dermatitis. Int J Mol Sci. 2020;21(15):5382.
van den Bogaard EH, Bergboer JG, Vonk-Bergers M, van Vlijmen-Willems I, Hato SV, van der Valk P, et al. Coal tar induces AHR-dependent skin barrier repair in atopic dermatitis. J Clin Invest. 2013;123(2):917-27.
Lebwohl MG, Stein Gold L, Strober B, Papp KA, Armstrong AW, Bagel J, et al. Phase 3 trials of tapinarof cream for plaque psoriasis. N Engl J Med. 2021;385(24):2219-29.
Strober B, Stein Gold L, Bissonnette R, Armstrong AW, Kircik L, Tyring SK, et al. One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: results from the PSOARING 3 trial. J Am Acad Dermatol. 2022;87:800-6.
Cai L, Chen GH, Lu QJ, Zheng M, Li YZ, Chen J, et al. A double-blind, randomized, placebo- and positive-controlled phase III trial of 1% benvitimod cream in mild-to-moderate plaque psoriasis. Chin Med J (Engl). 2020;133(24):2905-9.
Bissonnette R, Gold LS, Rubenstein DS, Tallman AM, Armstrong AW. The preponderance of evidence supports an aryl hydrocarbon receptor-dependent mechanism of action of tapinarof. J Am Acad Dermatol. 2021;85(1):e35-6.
Jett JE, McLaughlin M, Willson TM, Somerville M, DellaMaestra W, Rubenstein D, et al. Dermal safety of tapinarof cream 1%: results from 4 phase 1 trials. J Drugs Dermatol. 2022;21:1084-90.
Megna M, Caiazzo G, Parisi M, Ruggiero A, Capasso G, Mascolo M, et al. Eczematous drug eruption in patients with psoriasis under anti-interleukin-17A: does interleukin-22 play a key role? Clin Exp Dermatol. 2022;47(5):918-25.
Jett JE, McLaughlin M, Lee MS, Parish LC, DuBois J, Raoof TJ, et al. Tapinarof cream 1% for extensive plaque psoriasis: a maximal use trial on safety, tolerability, and pharmacokinetics. Am J Clin Dermatol. 2022;23(1):83-91.
Mooney N, Teague J, Gehad A, McHale K, Rubenstein DS, Clark RA. LB987 Tapinarof inhibits the formation, cytokine production, and persistence of resident memory T cells in vitro. J Invest Dermatol. 2022;142(8):B26.
Vu YH, Hashimoto-Hachiya A, Takemura M, Yumine A, Mitamura Y, Nakahara T, et al. IL-24 negatively regulates keratinocyte differentiation induced by tapinarof, an aryl hydrocarbon receptor modulator: implication in the treatment of atopic dermatitis. Int J Mol Sci. 2020;21(24):9412.